Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ImExHS Limited ( (AU:IME) ) has issued an announcement.
IMEXHS Limited, an ASX-listed medical imaging software and radiology services group, develops cloud-based, vendor-neutral SaaS platforms such as PACS, RIS, CIS and pathology information systems for hospitals and clinics across 18 countries. Its scalable, zero-footprint solutions target operational efficiency and cost savings while supporting better clinical outcomes in imaging-intensive care settings.
The company has secured a public tender to deploy its Aquila+ platform across 20 public hospitals and clinics in Zacatecas, Mexico, adding about $384,000 in new annual recurring revenue plus a $50,000 implementation fee. The rollout, which embeds five proprietary AI workflow agents and two Gleamer diagnostic algorithms, is expected to be completed by June 2026, reinforcing IMEXHS’s Mexico expansion strategy and showcasing one of the most comprehensive AI-integrated radiology deployments in a public health network to date.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
More about ImExHS Limited
IMEXHS Limited is an ASX-listed provider of cloud-based medical imaging software and radiology services operating in 18 countries, including Colombia, the U.S. and Australia. Its SaaS portfolio spans PACS, RIS, CIS and anatomical pathology laboratory systems, designed as vendor-neutral, zero-footprint solutions that improve productivity and patient outcomes for healthcare providers.
Average Trading Volume: 29,352
Technical Sentiment Signal: Sell
Current Market Cap: A$19.47M
See more insights into IME stock on TipRanks’ Stock Analysis page.